Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information on how we use and manage cookies please take a look at our privacy and cookie policies. Some parts of the site may not work properly if you choose not to accept cookies.

Home > UL EduNeering > Four Reasons Your FDA Compliance Training Is Not Preventing Violations

Four Reasons Your FDA Compliance Training Is Not Preventing Violations

White Paper Published By: UL EduNeering
UL EduNeering
Published:  Jul 05, 2012
Type:  White Paper
Length:  8 pages

For the past few years, the US pharmaceutical industry has been dragged across hot coals because of its marketing and sales practices. Misbranding or misrepresenting violations continue to erupt but another risk is rapidly taking over the headlines, court dockets and public opinion about our industry.

Good Manufacturing Practices (GMP) violations have become the new healthcare fraud as the Department of Justice (DOJ) tests out new legal theories under the False Claims Act (FCA). The Food and Drug Administration (FDA) has dusted off its regulatory authority to prosecute GMP violations. After blistering reports by government agencies, the FDA has ramped up inspections of domestic and foreign pharmaceutical plants - brand, generic, contract and Active Pharmaceutical Ingredient (API) - both in frequency and depth. And just to cement the growing public and legislative distrust of drug quality and safety, massive recalls have kept quality problems in the headlines and on the minds of millions of patients.

Tags : 
fda, gmp, gcp, gxp, cms, osha, qsr, 21 cfr part 11, regulatory compliance, pharmaceuticals, medical device, good manufacturing practices, quality system regulation, online compliance training, part 11 compliance, fda part 11 compliance, iso 13485, quality management system, life science, health care